Prophylactic Azithromycin Benefit Lasts After Lung Transplant

This article originally appeared here.
Share this content:
Prophylactic Azithromycin Benefit Lasts After Lung Transplant
Prophylactic Azithromycin Benefit Lasts After Lung Transplant

THURSDAY, Aug. 13, 2015 (HealthDay News) -- For patients undergoing lung transplantation (LTx), prophylactic azithromycin is associated with reduced risk of chronic lung allograft dysfunction (CLAD), according to a study published online Aug. 4 in the American Journal of Transplantation.

Noting that prophylactic azithromycin has been shown to improve freedom from bronchiolitis obliterans syndrome two years after LTx, David Ruttens, from KU Leuven and UZ Leuven in Belgium, and colleagues re-evaluated the long-term effects of this approach. They conducted a retrospective, intention-to-treat analysis of a randomized controlled trial comparing prophylactic treatment with placebo (43 patients) versus azithromycin (40 patients) after LTx. Seven years after the inclusion of the last subject, they examined CLAD, graft loss (re-transplantation, mortality), evolution of pulmonary function, and functional exercise capacity.

The researchers found that 51 percent of the placebo group and 28 percent of the azithromycin group ever developed CLAD after LTx (P = 0.043). The azithromycin group had longer CLAD-free survival (P = 0.024). The proportion of patients with obstructive versus restrictive CLAD was similar between the groups. The groups had similar graft loss: 53 percent in the placebo group versus 40 percent in the azithromycin group (P = 0.27). The azithromycin group had better long-term pulmonary function and functional exercise capacity (P < 0.05).

"In summary, our long-term follow-up data support a sustained benefit of post-transplant, prophylactic azithromycin in prolonging CLAD-free survival and preserving allograft function and exercise capacity," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths